Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension

Kidney International

Volumn 62, Issue 3, 2002, Pages 929-939

  Cheng, Hui Fang ^a   Wang, Connie J ^a   Moeckel, Gilbert W ^a   Zhang, Ming Zhi ^a   McKanna, James A ^a   Harris, Raymond C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetic nephropathy; Glomerular injury; Macula densa; PAI 1; SC58236; Prostaglandins; TGF ; Tubulointerstitial injury; VEGF

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CYCLOOXYGENASE 2 INHIBITOR; FIBRONECTIN; INSULIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG INHIBITION; EXTRACELLULAR MATRIX; HENLE LOOP; HYPERTENSION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CORTEX; KIDNEY DISEASE; KIDNEY INJURY; LONG TERM CARE; MACULA DENSA; MALE; MEDIATOR; MESANGIUM CELL; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; SCLEROSIS; SYSTOLIC BLOOD PRESSURE;

EID: 0036423877     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00520.x     Document Type: Article

References (78)

1. Kreisberg JI, Patel PY: The effects of insulin, glucose and diabetes on prostaglandin production by rat kidney glomeruli and cultured glomerular mesangial cells. Prostaglandins Leukot Med 11:431-442, 1983
2. Don BR, Blake S, Hutchison FN, et al: Dietary protein intake modulates glomerular eicosanoid production in the rat. Am J Physiol 252:F711-F718, 1989
3. Kirschenbaum MA, Chaudhari A: Effect of experimental diabetes on glomerular filtration rate and glomerular prostanoid production in the rat. Miner Electrolyte Metab 12:352-355, 1986
4. Craven PA, DeRubertis FR: Role for local prostaglandin and thromboxane production in the regulation of glomerular filtration rate in the rat with streptozocin-induced diabetes. J Lab Clin Med 113:674-681, 1989
5. Mathiesen ER, Hommel E, Olsen UB, Parving HH: Elevated urinary prostaglandin excretion and the effect of indomethacin on renal function in incipient diabetic nephropathy. Diabet Med 5:145-149, 1988
6. Moel DI, Safirstein RL, McEvoy RE, Hsueh W: Effect of aspirin on experimental diabetic nephropathy. J Lab Clin Med 110:300-307, 1987
7. Hommel E, Mathiesen E, Arnold-Larsen S, et al: Effects of indomethacin on kidney function in type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia 30:78-81, 1987
8. 2 and hyaluronan on mesangial cell proliferation. A potential contribution to glomerular hypercellularity in diabetes. Diabetes 45:44-50, 1996
9. Wolf G, Ziyadeh FN: Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 56:393-405, 1999
10. Needleman P, Turk J, Jakschik BA, et al: Arachidonic acid metabolism. Annu Rev Biochem 55:69-102, 1986
11. DeWitt DL, Smith WL: Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 85:1412-1416, 1988
12. Kujubu DA, Fletcher BS, Varnum BC, et al: TIS 10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266:12866-12872, 1991
13. Harris RC, McKanna JA, Akai Y, et al: Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94:2504-2510, 1994
14. Wang J-L, Cheng H-F, Zhang M-Z, et al: Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol 275:F613-F622, 1998
15. Sanchez PL, Salgaro LM, Ferreri NR, Escalante B: Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension 34(4 Pt 2):848-853, 1999
16. Wang J-L, Cheng H-F, Sheppel S, Harris RC: The cyclooxygenase-2 inhibitor, SC58326, decreases proteinuria and retards progression of glomerulosclerosis in the rat remnant kidney. Kidney Int 57:2334-2342, 2000
17. Penning TD, Talley JJ, Bertenshaw SR, et al: Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 40:1347-1365, 1997
18. Cheng HE, Burns KD, Harris RD: Reduced proximal tubule angiotensin II receptor expression in streptozotocin-induced diabetes mellitus. Kidney Int 46:1603-1610, 1994
19. Cheng HE, Wang JL, Zhang MZ, et al: Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest 103:953-961, 1999
20. Dworkin LD, Hostetter TH, Rennke HG, Brenner BM: Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension. J Clin Invest 73:1448-1461, 1984
21. Krolewski AS, Fogarty DG, Warram JH: Hypertension and nephropathy in diabetes mellitus: What is inherited and what is acquired? Diabetes Res Clin Pract 39(Suppl):S1-S14, 1998
22. Nelson RG, Pettitt DJ, Baird HR, et al: Pre-diabetic blood pressure predicts urinary albumin excretion after the onset of type 2 (non-insulin-dependent) diabetes mellitus in Pima Indians. Diabetologia 36:998-1001, 1993
23. Somova L, Dashev G, Kamenov V, et al: Streptozotocin-induced diabetes in rat. I. Influence of hypertension and myocardial infarction on the development of vascular complications. Exp Clin Pharmacol 10:677-682, 1988
24. Kang MJ, Ingram A, Ly H, et al: Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression. Kidney Int 58:1677-1685, 2000
25. Zatz R, Meyer TW, Rennke HG, Brenner BM: Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 82:5963-5967, 1985
26. Zatz R, Dunn BR, Meyer TW, et al: Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 77:1925-1930, 1986
27. Dworkin LD, Feiner HD, Randazzo J: Glomerular hypertension and injury in desoxycorticosterone-salt rats on antihypertensive therapy. Kidney Int 31:718-724, 1987
28. Komers R, Lindsley JN, Oyama TT, et al: Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 107:889-898, 2001
29. Cheng HE, Wang JL, Zhang MZ, et al: Role of p38 in the regulation of renal cortical cyclooxygenase-2 expression by extracellular chloride. J Clin Invest 106:681-688, 2000
30. 2 release and COX-2 expression in a mouse macula densa cell line. J Biol Chem 275:23281-23286, 2000
31. Zhang MZ, Harris RE, McKanna JA: Regulation of cyclooxygenase-2 (COX-2) in rat renal cortex by adrenal glucocorticoids and mineralocorticoids. Proc Natl Acad Sci USA 96:15280-15285, 1999
32. Vallon V, Richter K, Blantz RE, et al: Glomerular hyperfiltration in experimental diabetes mellitus: Potential role of tubular reabsorption. J Am Soc Nephrol 10:2569-2576, 1999
33. Thomson SC, Deng A, Bao D, et al: Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest 107:217-224, 2001
34. Yamamoto T, Nakamura T, Noble NA, et al: Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90:1814-1818, 1993
35. Shankland SJ, Scholey JV, Ly H, Thai K: Expression of transforming growth factor-beta 1 during diabetic renal hypertrophy. Kidney Int 46:430-442, 1994
36. Ziyadeh FN, Hoffman BB, Nan DE, et al: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015-8020, 2000
37. Cohen MP, Sharma K, Guo J, et al: The renal TGF-beta system in the db/db mouse model of diabetic nephropathy. Exp Nephrol 6:226-233, 1998
38. Hoffman BB, Sharma K, Ziyadeh FN: Potential role of TGF-beta in diabetic nephropathy. Miner Electrolyte Metab 24:190-196, 1998
39. Rocco M, Chen Y, Goldfarb S, Ziyadeh FN: Elevated glucose stimulates TGF-β expression and bioactivity in proximal tubule. Kidney Int 41:107-114, 1992
40. Han DC, Isono M, Hoffman BB, Ziyadeh FN: High glucose stimulates proliferation and collagen type I synthesis in renal cortical fibroblasts: Mediation by autocrine activation of TGF-beta. J Am Soc Nephrol 10:1891-1899, 1999
41. Schleicher E, Nerlich A, Gerbitz KD: Pathobiochemical aspects of diabetic nephropathy. Klin Wochenschr 66:873-882, 1988
42. Ikeda S, Makino H, Haramoto T, et al: Changes in glomerular extracellular matrices components in diabetic nephropathy. J Diabet Compl 5:186-188, 1991
43. Nerlich A, Schleicher E: Immunohistochemical localization of extracellular matrix components in human diabetic glomerular lesions. Am J Pathol 139:889-899, 1991
44. Kreisberg JI, Ayo SH: The glomerular mesangium in diabetes mellitus. Kidney Int 43:109-113, 1993
45. Fogo AB: Mesangial matrix modulation and glomerulosclerosis. Exp Nephrol 7:147-159, 2000
46. Rerolle JP, Hertig A, Nguyen G, et al: Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 58:1841-1850, 2000
47. Tomooka S, Border WA, Marshall BC, Noble NA: Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. Kidney Int 42:1462-1469, 1992
48. Cooper ME, Vranes D, Youssef S, et al: Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48:2229-2239, 1999
49. Gruden G, Thomas S, Burt D, et al: Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol 10:730-737, 1999
50. Christiansen JS, Gammelgaard J, Frandsen M, Parving HH: Increased kidney size, glomerular filtration rate and renal plasma flow in short-term insulin-dependent diabetics. Diabetologia 20:451-456, 1981
51. Wolf G, Mueller E, Stahl RA, Ziyadeh FN: Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 92:1366-1372, 1993
52. Ziyadeh FN, Sharma K: Role of transforming growth factor-beta in diabetic glomerulosclerosis and renal hypertrophy. Kidney Int 48(Suppl 51):S34-S36, 1995
53. Sharma K, Jin Y, Guo J, Ziyadeh FN: Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45:522-530, 1996
54. Feng L, Sun W, Xia Y, et al: Cloning two isoforms of rat cyclooxygenase: Differential regulation of their expression. Arch Biochem Biophys 307:361-368, 1993
55. Klahr S, Morrissey JJ: The role of growth factors, cytokines, and vasoactive compounds in obstructive nephropathy. Semin Nephrol 18:622-632, 1998
56. Takahashi K, Schreiner GF, Yamashita K, et al: Predominant functional roles for thromboxane A2 and prostaglandin E2 during late nephrotoxic serum glomerulonephritis in the rat. J Clin Invest 85:1974-1982, 1990
57. Badr K: Arachidonic acid metabolites in glomerular immune injury. Semin Nephrol 11:332-339, 1991
58. Nath KA, Chmielewski DH, Hostetter TH: Regulatory role of prostanoids in glomerular microcirculation of remnant nephrons. Am J Physiol 252(5 Pt 2):F829-F837, 1987
59. Bergstein JM: Prostaglandin inhibitors in the treatment of nephrotic syndrome. Pediatr Nephrol 5:335-338, 1991
60. Dunn MJ: Prostaglandins, angiotension II, and proteinuria. Nephron 55(Suppl 1):30-37, 1990
61. Vriesendorp R, Donker AJ, De Zeeuw D, et al: Effects of nonsteroidal anti-inflammatory drugs on proteinuria. Am J Med 81:84-94, 1986
62. Heeg JE, De Jong PE, Vriesendorp R, De Zeeuw D: Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril. Am J Nephrol 10(Suppl 1):94-97, 1990
63. Murray BM, Brown GP: Effect of protein intake on the autoregulation of renal blood flow. Am J Physiol 258:F168-F174, 1990
64. Pelayo JC, Westcott JY: Impaired autoregulation of glomerular capillary hydrostatic pressure in the rat remnant nephron. J Clin Invest 88:101-105, 1991
65. Hayashi K, Epstein M, Loutzenhiser R, Forster H: Impaired myogenic responsiveness of the afferent arteriole in streptozotocin-induced diabetic rats: Role of eicosanoid derangements. J Am Soc Nephrol 2:1578-1586, 1992
66. Wilke WL, Persson AE: Captopril and tubuloglomerular feedback in remnant kidneys of prehypertensive rats. J Am Soc Nephrol 3:73-79, 1992
67. Seney FD Jr, Wright FS: Dietary protein suppresses feedback control of glomerular filtration in rats. J Clin Invest 75:558-568, 1985
68. Seney FD Jr, Persson EG, Wright FS: Modification of tubuloglomerular feedback signal by dietary protein. Am J Physiol 252(1 Pt 2):F83-F90, 1987
69. Ichihara A, Imig JD, Inscho EW, Navar LG: Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: Interaction with neuronal NOS. Am J Physiol 275(4 Pt 2):F605-F612, 1998
70. Negrete H, Studer R, Craven P, DeRubertis F: Role for transforming growth factor beta in thromboxane-induced increases in mesangial cell fibronectin synthesis. Diabetes 44:335-339, 1995
71. Studer R, Negrete H, Craven P, DeRubertis F: Protein kinase C signals thromboxane induced increases in fibronectin synthesis and TGF-beta bioactivity in mesangial cells. Kidney Int 48:422-430, 1995
72. Zoja C, Perico N, Corna D, et al: Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney. J Am Soc Nephrol 1:799-807, 1990
73. Purkerson ML, Joist JH, Yates J, et al: Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. Proc Natl Acad Sci USA 82:193-197, 1985
74. Stahl RA, Thaiss F, Wenzel U, et al: A rat model of progressive chronic glomerular sclerosis: The role of thromboxane inhibition. J Am Soc Nephrol 2:1568-1577, 1992
75. Schmitz PG, Krupa SM, Lane PH, et al: Acquired essential fatty acid depletion in the remnant kidney: Amelioration with U-63557A. Kidney Int 46:1184-1191, 1994
76. Tajiri Y, Inoguchi T, Umeda F, Nawata H: Reduction of urinary albumin excretion by thromboxane synthetase inhibitor, OKY-046, through modulating renal prostaglandins in patients with diabetic nephropathy. Diabetes Res Clin Pract 10:231-239, 1990
77. Tajiri Y, Umeda F, Inoguchi T, Nawata H: Effects of thromboxane synthetase inhibitor (OKY-046) on urinary prostaglandin excretion and renal function in streptozotocin-induced diabetic rat. J Diabetes Compl 8:126-132, 1994
78. Masumura H, Kunitada S, Irie K, et al: A thromboxane A2 synthetase inhibitor retards hypertensive rat diabetic nephropathy. Eur J Pharmacol 210:163-172, 1992